Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ritonavir-boosted Danoprevir in Healthy Volunteers
NCT03019991Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of danoprevir in hepatitis C (HCV) (2 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Incidence of adverse events at 40 days, Maximum plasma concentration at steady-state up to 16 days and 1 more. Started Oct 2015; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03019991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019991.